
A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
Keywords: BET inhibitor; apoA-I-inducer; RVX-208; Atherosclerosis; Preβ-HDL; Inflammation; apoE deficient; apoA-I; apolipoprotein A-I; BET; bromodomain and extra terminal; CVD; cardiovascular disease; CAD; coronary artery disease; ChreBP; carbohydrate response ele